Pages that link to "Q36866954"
Jump to navigation
Jump to search
The following pages link to Improvements in patient-reported outcomes with apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of moderate to severe psoriasis: results from a phase IIb randomized, controlled study (Q36866954):
Displaying 22 items.
- Drug treatments for pruritus in adult palliative care (Q26825684) (← links)
- Oral Apremilast for the Treatment of Plaque Psoriasis (Q28075724) (← links)
- The anti-inflammatory and immunomodulatory potential of braylin: Pharmacological properties and mechanisms by in silico, in vitro and in vivo approaches (Q33778757) (← links)
- Fractional carbon dioxide laser resurfacing of rhytides and photoaged skin--a prospective clinical study on patient expectation and satisfaction (Q35555246) (← links)
- Small Molecules in the Treatment of Psoriasis (Q35740706) (← links)
- Apremilast (Otezla): A New Oral Treatment for Adults With Psoriasis and Psoriatic Arthritis. (Q35896444) (← links)
- A meta-analysis of apremilast on psoriatic arthritis long-term assessment of clinical efficacy (PALACE). (Q35937121) (← links)
- Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3) (Q36968787) (← links)
- Tofacitinib versus etanercept or placebo in patients with moderate to severe chronic plaque psoriasis: patient-reported outcomes from a Phase 3 study (Q37412781) (← links)
- Effect of tofacitinib withdrawal and re-treatment on patient-reported outcomes: results from a Phase 3 study in patients with moderate to severe chronic plaque psoriasis. (Q37631750) (← links)
- East Indian Sandalwood Oil (EISO) Alleviates Inflammatory and Proliferative Pathologies of Psoriasis (Q37703061) (← links)
- Apremilast, an oral phosphodiesterase 4 inhibitor, improves patient-reported outcomes in the treatment of moderate to severe psoriasis: results of two phase III randomized, controlled trials (Q37717828) (← links)
- Systemic therapies for psoriasis: an evidence-based update. (Q38185297) (← links)
- Apremilast: first global approval (Q38209439) (← links)
- Inhibitors of phosphodiesterase 4 (PDE 4): A new therapeutic option in the treatment of psoriasis vulgaris and psoriatic arthritis (Q38271333) (← links)
- Apremilast: a PDE4 inhibitor for the treatment of psoriatic arthritis (Q38416536) (← links)
- Apremilast: A Novel Drug for Treatment of Psoriasis and Psoriatic Arthritis (Q38702419) (← links)
- A systematic review of the use of quality-of-life instruments in randomized controlled trials for psoriasis (Q38858335) (← links)
- Apremilast for the management of moderate to severe plaque psoriasis (Q39170240) (← links)
- Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. (Q47260366) (← links)
- Too many instruments for measuring Quality of Life in Atopic Dermatitis. (Q52839851) (← links)
- Improvement in Patient-Reported Outcomes (Dermatology Life Quality Index and the Psoriasis Symptoms and Signs Diary) with Guselkumab in Moderate-to-Severe Plaque Psoriasis: Results from the Phase III VOYAGE 1 and VOYAGE 2 Studies. (Q64897976) (← links)